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Abstract
Takotsubo cardiomyopathy (TCM) is  a  life-threatening systemic disorder that  may
occur early after aneurysmal subarachnoid hemorrhage (SAH), but precise hemody-
namics and fluid management remain unclear. Although TCM is often regarded as a
reversible or self-limited phenomenon, it contributes significantly to morbidity and
mortality of SAH patients, especially when it is complicated with other neurogenic
injuries such as severe left ventricular dysfunction, pulmonary edema, and pneumonia.
The purpose of this chapter is to introduce the current practice in intensive hemody-
namic  monitoring  and  goal-directed  fluid  management  of  post-SAH  TCM  using
advanced hemodynamic devices based on our institutional protocol and the relevant
literature and to evaluate their effects on clinical outcomes.
Keywords: Takotsubo cardiomyopathy, neurogenic stress cardiomyopathy, fluid ther-
apy, pulmonary edema, subarachnoid hemorrhage
1. Introduction
Postoperative management of aneurysmal subarachnoid hemorrhage (SAH) is sometimes
complicated by systemic cardiopulmonary complications to affect a significant impact on the
morbidity and mortality of the patients [1, 2]. The neuro-cardiac injury of SAH is of particular
importance because of their impact on the ability to manage blood pressure and volume status,
especially in the setting of cerebral vasospasm or delayed cerebral ischemia (DCI). The pattern
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of injury produced is commonly referred to as neurogenic stress cardiomyopathy [3]. One
distinct morphological variant of stress cardiomyopathy is Takotsubo cardiomyopathy (TCM),
which was first described by the Japanese physician in the early 1990s to be a reversible
cardiomyopathy, the shape of which named after an octopus trap used by the native fishermen
[4]. Although TCM is typically associated with acute emotional stress in postmenopausal
women [5], triggers may also include physical stressors such as head trauma, intracranial
bleeding, ischemic stroke, medical, and surgical procedures and catecholaminergic drugs [6].
Previous reports suggest the demographics and clinical characteristics of TCM are similar
irrespective of their etiologies. However, there are notable differences in post-SAH TCM from
other non-neurologic stressors in that the patients tended to be younger and more frequent in
females than what is typically reported and had high in-hospital mortality (25%) [7].
Figure 1. Subarachnoid hemorrhage-induced neurogenic injuries. Note that apical ballooning suggestive of Takotsubo
cardiomyopathy (TCM) and left ventricular dysfunction detected by apical two-chamber view on initial echocardio-
gram. Acute pulmonary edema was also observed on chest X-ray. 123I-metaiodobenzylguanidine (MIBG) SPECT depict-
ing apical defect in the two-chamber view and the analysis of two-dimensional polar maps (bull’s eyes) show
decreased myocardial perfusion in apex. In 4-h delayed images, washout is increased, suggesting the presynaptic sym-
pathetic dysfunction caused by TCM.
TCM is originally characterized by transient hypokinesis which results from apical wall motion
abnormalities with sparing of the base. Although most of the TCM patients (>65%) can present
such typical patterns on echocardiography (Figure 1), there are several different variants of
regional wall motion abnormalities (RWMA) that spares the cardiac apex, as well as one that
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affects the right ventricle. The right ventricle involvement is noted in 26% of the patients with
TCM and bilateral pleural effusions are commonly seen in these patients [8].
The diagnosis of TCM is made based on a modified version of the Mayo Clinic Criteria [9] as
described in Table 1.
1. Transient hypokinesis, akinesis or dyskinesis of the LV mid-segments with or without apical involvement; the
RWMA extend beyond a single epicardial vascular distribution; a stressful trigger is often, but not always, present.
2. Absence of obstructive coronary artery disease or angiographic evidence of acute plaque rupture.
3. New ECG abnormalities (either ST elevation and/or T wave inversion) or modest elevation in cardiac troponin.
4. Absence of other precipitants such as pheochromocytoma and myocarditis.
LV: left ventricular; RWMA: regional wall motion abnormalities; ECG: electrocardiogram.
Table 1. The Mayo Clinic published diagnostic criteria for TCM after SAH.
Patients with akinesis or hypokinesis of left ventricular (LV) apical segments with preserved
contractility of the basal segments are considered to have the apical variant of TCM (apical
ballooning), while those with akinesis of the basal segments with preserved contractility of
the apex and mid-ventricular segments are classified as having reverse TCM (non-apical
ballooning).
A massive release of catecholamines into the systemic circulation after aneurysmal rupture
has been considered responsible for SAH-induced TCM. In view of the literature reviews
(Table 1), the incidence of TCM in SAH patients ranges from 0.8 to 17% [1, 2, 7, 10–12], which
makes it a relatively common postoperative complication. However, the management of TCM
becomes cumbersome in the setting of volumetric and hemodynamic therapy for DCI. In this
chapter, we will review the current practice in intensive hemodynamic monitoring and goal-
directed fluid management of post-SAH TCM using advanced hemodynamic devices based
on our institutional protocol and the relevant literature and to evaluate their effects on clinical
outcomes (Table 2 ).
Total
number
TCM
[n (%)]
LVEF <40%
[n (%)]
Mean age
(years)
Female
(%)
Poor
grade (%)
DCI (%) Poor
outcome
(%)
Mutoh et al. [12] 575 46 (8) 20 (43) 64 70 87 33 48
Talahma et al. [1] 800 18 (2.2) N/A 63 78 33 N/A 44
Kilbourn et al. [2] 63 11 (17) N/A 61 72 82 N/A 80
Inamasu et al. [10] 391 30 (7.7) 8 (27) 62 63 83 27 57
Abd et al. [7] 2276 19 (0.8) 14 (74) 45 100 58 N/A N/A
Lee et al. [11] 661 8 (1.2) 4 (50) 56 100 88 38 N/A
Table 2. Incidence and characteristics of TCM in patients after subarachnoid hemorrhage.
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2. Pathophysiology of post-SAH TCM
The underlying mechanism of TCM is not fully understood. Several theories have been
proposed to explain its pathophysiology including excessive sympathetic stimulation,
microvascular dysfunction, coronary artery vasospasm, and abnormal myocardial tissue
metabolism [1]. An excessive release of catecholamines (catecholamine surge or sympathetic
storming) immediately after insult associated with aneurysm rupture seems to have a pivotal
role in the development of TCM. In fact, patients with TCM are at risk for fatal arrhythmias
particularly those with SAH combined with intra-sylvian/intracerebral hematoma that
involves the right insular cortex where sympathetic hyperactivation can occur [13, 14].
The deleterious effect of such brain–heart interactions may contribute to explain the observa-
tion that the outcome of patients with SAH can be predicted by measuring the levels of
circulating catecholamine or myocardial sympathetic function. Using an isotope dilution
technique, Naredi et al. [15] suggest that patients with subarachnoid hemorrhage exhibited a
threefold increase in plasma norepinephrine within 48 h persisted throughout 7–10 days and
normalized thereafter. Indeed, nuclear imaging using 123I-meta-iodobenzylguanidine (MIBG),
a radioactive marker allowing mapping of the autonomic nervous system of the heart also
support the existence of sympathetic dysfunction (Figure 1) as a result of overactivation in the
area of ventricular wall dysfunction with preserved coronary blood flow [16].
Histopathological findings support this theory since patients presented with typical TCM
showed extensive area of myocardial thinning and myocyte edema at the cardiac apex in which
degenerative myocardium with histiocyte and lymphocyte infiltration, and contracture-like
necrotic bands, but a less severe pathology at the base [17, 18]. Oxidative stress can lead to
myocardial necrosis, remodelling, and contractility disturbances [8]. Neuropathological
evidence of Lewy body-like cytoplasmic inclusions in both dorsal nuclei of the vagus nerve
suggests that disorders of the parasympathetic nervous system may also be associated with a
consequence of TCM [17].
On the other hand, the predominance of TCM in female subjects implicates possible properties
of genetic predisposition and/or estrogen deficiency [8]. Goodloe et al. [19] investigated
functional adrenergic polymorphisms in 28 TCM patients to suggest that TCM was enriched
for variants within functional domains, although the polymorphism frequencies were similar
to population controls as described previously. Kuo et al. [20] presented a case series of 18 TCM
patients and concluded that the lack of estrogen replacement in the postmenopausal state may
predispose women to Takotsubo cardiomyopathy. Based on the results from TCM in a mother–
sister pair, it has been suggested that the segregating rare variants in four genes (ADH5,
CACNG1, EPHA4, and PRKCA) [19] may synergistically confer myocardial vulnerability and
risk for TCM in the setting of a postmenopausal hormonal environment and a catecholamine
trigger.
The available literature provides no clear answer about the safety of general anesthesia in SAH
patients complicated with TCM, and whether the treatment of the aneurysms should be
surgical or endovascular. However, it appears that TCM may not be a contraindication to
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surgical obliteration of the aneurysms as long as the patient is hemodynamically stable [10],
while multiple other reports showed that endovascular intervention is the preferred modality
of treatment in these patients [21]. In fact, 37–61% of patients underwent surgical clipping for
their aneurysms which elucidate the safety of anesthesia for microsurgical clipping even in the
setting of TCM [1, 10, 12]. Furthermore, neither clipped nor coiled patients developed serious
perioperative cardiopulmonary complications, although relatively higher incidence of fatal
procedure-related complications was demonstrated in patients underwent coiling [10].
3. Hemodynamics of TCM after SAH
The hemodynamic changes of TCM that occur during the course of SAH are not fully under-
stood, presumably because of the complicated underlying acute pathophysiological mecha-
nisms that could merely be an innocent finding reflecting the general population.
Although the RWMA associated with TCM is transient with resolution generally within
several days to weeks [22, 23], it contributes significantly to cardiopulmonary hemodynam-
ics following SAH, especially when it is combined with other neurogenic injuries such as
pulmonary edema, cardiogenic shock, and life-threatening arrhythmia [24, 25]. The RWMA
diagnosed on echocardiography have been reported in up to 20% of patients after SAH [2],
which is sometimes extensive enough to reduce left ventricular ejection fraction (LVEF).
Therefore, in addition to pulmonary edema and hypoxia, TCM may lead to low cardiac
output (CO) and hypotension to reduce cerebral perfusion pressure. The incidence of SAH-
induced LV dysfunction has been estimated at around 5–10% [26], the development of which
following TCM can increase the risk of DCI [11, 27] and poor outcome [12]. Moreover, TCM
is associated with a 25% incidence of left ventricular outflow tract (LVOT) obstruction [28],
and thus we have to be carefully monitor the cardiac functions to avoid increased intraven-
tricular pressure gradient particularly when treating the related cardiogenic shock or post-
SAH DCI.
4. Intensive fluid management for post-SAH TCM
4.1. Hemodynamic monitoring
Cardiovascular monitoring is essential for the diagnostic and therapeutic management of
critically ill patients. Of particular, early hemodynamic assessment is importance for adequate
cerebral circulation in patients with SAH. Echocardiography is currently the most frequently
used noninvasive imaging modality for bedside assessment of LV function [29–31], but is not
ideal for real-time monitoring of systolic function because of its high intra- and inter-observer
variability [32].
Hemodynamic monitoring is essential for the diagnosis and therapeutic management of
critically ill patients. Several different methods and techniques are used to monitor patients
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with cardiopulmonary complications, although none are ideal (i.e., noninvasive, safe, repro-
ducible, assessing both preload and lung edema volumes, as well as cardiac function) [33].
Unfortunately, the use of such monitoring devices has been limited in neurocritical care,
presumably due to inexperience and complexity of handling multiple hemodynamic param-
eters (e.g., pulmonary artery catheter) [34]. Recently, several studies examined acute hemo-
dynamic changes following SAH using an advanced bedside transpulmonary thermodilution
(TPTD) device [12, 35–38].
The single-indicator TPTD method incorporated into the PiCCO/PulsioFlex (Pulsion Medical
Systems, Munich, Germany) or EV-1000 (Edwards Lifesciences, Irvine, CA, USA) system
measures the change in temperature over time at a thermistor-tipped peripheral arterial
catheter inserted into the femoral or brachial artery by triplicate injections of 15-mL boluses of
ice-cold saline via the central venous line [39]. The TPTD algorithm calculates CO by analysis
of the thermodilution curve using the Stewart–Hamilton equations, which are less-invasive
but comparable with those by the established PAC technique [40].
The accuracy of continuous CO measurements, superiority of the TPTD-derived volumetric
parameters for estimating cardiac preload (based on global end-diastolic volume (GEDV))
compared with measurement using fluid balance, central venous pressure or a pulmonary
artery catheter [41], and the utility of EVLW to discriminate pulmonary edema [37, 42] have
been validated in clinical studies in SAH. These hemodynamic data can provide to analyze
the cardiac function index (CFI, normal value: 4.5–6.5 per minute), which is the ratio of CO
to GEDV [39]. Previous data suggest that CFI is closely related to the LV fractional area of
change measured by echocardiography [43] and that CFI can be used to accurately assess
the effects of positive inotropic therapy with dobutamine in acute circulatory failure [29].
4.2. Hemodynamic parameters for monitoring TCM
We have recently demonstrated that CFI measured by TPTD provides reliable real-time
estimation of LV systolic function in 46 patients with TCM [12]. This study has an advantage
of including the largest reported number of patients with post-SAH TCM who were success-
fully monitored for cardiac performance and volume status for approximately 14 days. CFI
behaves like an index of LV systolic function because (1) it is fairly well correlated with the
echocardiographic LVEF and reliably tracks treatment-induced changes in LVEF, and (2) it is
not affected by fluid loading, but increased after administration of an inotropic agent. The
decrease in CFI of <4.0 per minute is valuable for detecting LV dysfunction in TCM defined by
LVEF <40% (sensitivity of 82% and specificity of 84%), which is the point at which inotropic
support should be considered.
At initial measurement on day 0 during the first 24 h after SAH, depression of LV systolic
function (CFI 3.3 per minute) mainly attributable to low CO (2.2 L/min/m2) was observed
for patients with TCM. Hypovolemia defined by decreased GEDV (635 mL/m2) was notable
in patients with LV dysfunction (LVEF <40%). In our population, we could not detect any
significant difference in HR, MAP, CVP, or SVRI between the groups with and without
LV dysfunction throughout the acute period of 2 weeks after SAH. It has also been
suggested that TCM combined with LV dysfunction has a longer duration of low CFI
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(<4.0 per minute, corresponding to predicted LVEF <40% [29]) with a mean difference of
4 days and more frequencies of pulmonary edema defined by EVLW > 14 mL/kg after
day 4 (55%) (Figure 2).
4.3. Choice of drugs for post-SAH TCM patients
Medical treatment of arterial vasospasm following aneurysmal subarachnoid hemorrhage
(SAH) generally consists of triple H (hypertensive-hypervolemia-hemodilution) therapy [44,
45] or its modification [46–48], which frequently relies on inotropic agents in order to increase
CO. Although the optimal treatment is still a matter of debate, given the relationship between
catecholamine hypersecretion and subsequent development of TCM, intensivists are often
Figure 2. Changes in hemodynamic parameters over 2 weeks in 30 patients with Takotsubo cardiomyopathy following
subarachnoid hemorrhage. Note that cardiac function index more clearly traces changes in cardiac function than car-
diac output particularly in patients with left ventricular dysfunction [ejection fraction (EF) < 40%]. Increased extrava-
scular lung water in this subgroup can also be detected. Modified with permission from Ref. [12].
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reluctant to use inotropes and vasopressors even in patients who may benefit from cardiogenic
shock or hemodynamic therapy for DCI. Although there is general agreement in the literature
about avoiding vasopressors in TCM patients because of the adverse effects on catecholamine
hypersensitivity, the recent data suggest that vasopressors may be used safely by careful
monitoring of the hemodynamic parameters [1, 49]. In fact, most patients (61%) had already
been administered vasopressors prior to the diagnosis of TCM, in which more than 60%
remained on the same treatment and most of them (86%) had good outcome [1]. There is only
a case of TCM reported as a direct effect of catecholamine stimulation, including an anecdotal
case of de novo TCM in a patient treated with dobutamine for symptomatic SAH vasospasm
[50]. In select patients, the use of intra-aortic balloon pump (IABP) may be beneficial as an
adjunctive therapy of patients with comorbid DCI and TCM who become intolerant to
aggressive pharmacologic hemodynamic augmentation [51].
Milrinone could be a good alternative when inotropes are required in TCM and when
dobutamine infusion is associated with tachycardia [52]. The use of milrinone has been
proposed to augment the cerebral perfusion in TCM giving its combined inotropic and
vasodilating properties [53]. Milrinone is a phosphodiesterase-III inhibitor that increases
calcium influx in the myocardium which leads to increased cardiac contractility without β-
agonist action, resulting in less tachycardia [52] and myocardial oxygen consumption [54].
However, milrinone may induce hypotension as a result of peripheral vasodilatory property,
which may require intensive hemodynamic monitoring during the management.
In the case of concurrent LVOT obstruction associated with post-SAH TCM that may have a
paradoxical decrease in CO following administration of inotropic pressors, discontinuation of
the inotropes and maintenance of hypervolemia may be required in order to optimize cerebral
perfusion and prevent ischemia [27]. If a patient with TCM is deteriorating and has a low CO
with LVOT, cardiogenic shock, and progressive multiorgan failure, temporary LV assist
devices (LVAD) or extracorporeal membrane oxygenation (ECMO) as a bridge-to-recovery
may be useful, as there is a possibility that the ventricular function will recover fully [55].
The role of β-blockers in SAH patients with TCM remains unclear. Patients who had been
treated with β-blockers prior to the SAH were associated with a lower risk of developing TCM
[56]. In one small study (n = 18), the use of β-blockers prior to or after the diagnosis of TCM
was not associated with a significant difference in neurological outcome [1]. The role of a newer
inotropic agent levosimendan is more controversial, with mixed expert opinion based on
preclinical and limited clinical experience [1, 55]. Future studies on the effectiveness of these
drugs in prevention or treatment of TCM may be warranted in larger population.
4.4. TPTD-guided early goal-directed fluid management
Fluid management of peri- and postoperative SAH patients is aimed primarily at maintaining
CO to increase cerebral blood flow, and at preventing hypovolemia by minimizing cardiopul-
monary complications [44, 57, 58]. The practical usefulness of early goal-directed fluid therapy
(EGDT) with TPTD has been proposed in SAH patients including those suffered from TCM
[12, 36, 37, 41, 42, 59].
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Hemodynamic stability is defined as CO ≥3 L/min/m2, GEDV ≥680 mL/m2, and ELWI ≤14
mL/kg (the upper limits chosen were the values associated with a higher risk of mortality in
patients with pulmonary edema) [60]. If CO fell below the target value due to hypovolemia,
patients received 500 mL of either crystalloid fluid or 6% hydroxyethyl starch. If this fluid
loading did not increase the GEDV to above the target value, and the low CO persisted for at
least 8 h, 25% albumin solution was administered. If the low CO persisted even with hypervo-
lemia (GEDV ≥ 850 mL/m2) and fluid therapy for at least 12 h, inotropic support was initiated
with dobutamine [61] or milrinone [12, 37] to maintain CO above the target value. If the patient
had elevated EVLW (>14 mL/kg) and any signs of congestive heart failure or pulmonary edema
(such as bilateral pulmonary infiltrates or cardiomegaly with a cardiothoracic ratio >50% on
chest radiography), furosemide (5 mg bolus) was administered intravenously.
According to our institutional protocol, clinical deterioration due to DCI or evidence of cerebral
vasospasm on transcranial Doppler ultrasonography (mean flow velocity in the middle
cerebral artery >120 cm/s) was treated with hyperdynamic therapy with incremental doses of
dobutamine (3 µg/kg/min, maximum 15 µg/kg/min) or milrinone (0.125 µg/kg/min, maximum
0.75 µg/kg/min) to raise the CO above the normal limit (>5.0 L/min/m2) or to resolve the deficit
[12, 62, 63]. Recovery of RWMA [64] and the absence of LVOT obstruction were confirmed by
echocardiography before the initiation of hyperdynamic therapy to avoid adverse effects due
to the use of inotropic agents [27].
4.5. Outcome of EGDT in post-SAH TCM
In TCM patients managed with aforementioned post-SAH EGDT, multivariate logistic
regression analysis showed that persisted low CFI (<4.0 per minute) for ≥4 days was inde-
pendently associated with DCI (odds ratio, 1.87) and poor functional outcome at 3 months
(modified Rankin Scale of 4–6: odds ratio, 1.92). In addition, coexisting pulmonary edema
(EVLW > 12 mL/kg) also increased the risk of poor functional outcome at 3 months (odds ratio,
1.85). The results may have an advantage of EGDT because neither a lower LEVF nor the
presence of concomitant pulmonary edema correlated with unfavorable outcomes in 30 SAH
patients with TCM managed by conventional fluid management using echocardiography and
standard hemodynamic parameters [10]. Furthermore, the finding that EGDT has a lower
incidence of therapy-related pulmonary edema than standard care [65] may support the value
of intensive hemodynamic monitoring.
5. Conclusion
TCM is a well-recognized neurogenic stress-induced complication early after SAH. It is a self-
limiting condition but often adds an additional layer of clinical morbidity to a patient partic-
ularly suffering from DCI. Our clinical data suggest that prolonged cardiac dysfunction and
concurrent pulmonary edema can increase the risk of DCI, contributing to poor functional
outcome in patients with SAH complicated with TCM. Serial measurements of CFI and EVLW
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may provide an easy bedside method of estimating changes in LVEF in TCM and predicting
the outcome, as well as detecting fluid therapy-related cardiopulmonary complications.
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